NEOFORDEX (dexamethasone), glucocorticoid
ONCOLOGY - NEW PRESENTATION
Opinions on drugs - Posted on Jul 05 2017
Reason for request
Minor clinical added value for this medicine based on dexamethasone at 40 mg compared to DECTANCYL (dexamethasone 0.5 mg) in the context of symptomatic multiple myeloma therapeutic protocols
- NEOFORDEX has marketing authorisation for adults, in combination, for the treatment of symptomatic multiple myeloma.
- The use of corticosteroid therapy has been established for many decades in haematological malignancies and especially multiple myeloma.
- The dexamethasone form of NEOFORDEX 40 mg is more suitable than the 0.5 mg form.
Clinical Added Value
Évaluation des médicaments